These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 604137)

  • 1. Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines.
    Kuwert EK; Höher PG; Werner J; Scheiermann N; Thraenhart O; Müller B; Kleber G
    Dev Biol Stand; 1977 Jun 1-3; 39():77-83. PubMed ID: 604137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials with a new influenza subunit vaccine in adults and children.
    Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz AJ
    Dev Biol Stand; 1977 Jun 1-3; 39():297-302. PubMed ID: 342311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA; Cate TR; Nino D; Huggins LL; Six HR; Quarles JM; Couch RB
    J Infect Dis; 2001 Jan; 183(2):329-332. PubMed ID: 11110645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G; Greenbaum E; Zakay-Rones Z
    Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
    Beutner KR; Rizzone C; DeMello S; Ogra PL
    Dev Biol Stand; 1976; 33():162-70. PubMed ID: 782964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of humoral immune response to influenza vaccines by BCG.
    Zykov MP; Subbotina TI
    Acta Virol; 1985 Sep; 29(5):403-9. PubMed ID: 2866694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza I. Hemagglutinationinhibiting antibodies (author's transl)].
    Kuwert EK; Werner J; Scheiermann N; Pledt T
    Zentralbl Bakteriol Orig A; 1979 Jul; 244(2-3):155-74. PubMed ID: 506543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
    Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
    Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response in humans after administration of whole-virion and split vaccine prepared from two different influenza A/swine viruses.
    Závadová H; Vonka V; Domorázková E; Syrůcek L; Stárek M; Hrusková J; Plesník V; Janout V; Uvízl M
    Dev Biol Stand; 1977 Jun 1-3; 39():231-4. PubMed ID: 604101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics and specificity of influenza virus antibodies as well as IgE values in serum and nasal fluid after repeated local application of live bivalent influenza vaccine.
    Werner J; Kuwert EK
    Dev Biol Stand; 1977 Jun 1-3; 39():135-40. PubMed ID: 604096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live tissue culture influenza vaccine for oral administration. I. Specific immune response to monovaccine A (H3N2) in volunteers.
    Alekseeva AK; Andzhaparidze OG; Gracheva EN; Sidorova LA; Melnikova SK
    Acta Virol; 1979 Jan; 23(1):59-66. PubMed ID: 35960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1).
    Schmidt S; Süss J; Oehring H; Schmidt J
    Acta Virol; 1982 Dec; 26(6):466-73. PubMed ID: 6132540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
    Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
    J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity to influenza in older adults with chronic obstructive pulmonary disease.
    Gorse GJ; O'Connor TZ; Newman FK; Mandava MD; Mendelman PM; Wittes J; Peduzzi PN
    J Infect Dis; 2004 Jul; 190(1):11-9. PubMed ID: 15195238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of live attenuated influenza vaccine ts-1(E) in man.
    Gwaltney JM
    Dev Biol Stand; 1976; 33():178-83. PubMed ID: 782966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody formation in laboratory animals after parenteral application of A/swine influenza virus.
    Dolezalová B; Závadová H; Stárek M; Vonka V
    Dev Biol Stand; 1977 Jun 1-3; 39():405-8. PubMed ID: 604122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.